A polygenic risk score (PRS) based on genes associated with endothelial cell function identifies patients at a higher risk of coronary artery disease, according to a new study. The risk score, which ...
Emmecell receives FDA RMAT designation for EO2002, advancing development of its regenerative cell therapy for corneal endothelial disease.